Showing results (41-50 of 200) with videos related to
Sort By:
Pageof 20
Arthritis and Rheumatism|June 3, 2008
Evidence of a novel aggrecan-degrading activity in cartilage: Studies of mice deficient in both ADAMTS-4 and ADAMTS-5Fraser M Rogerson, Heather Stanton, Charlotte J East, et al.The International Journal of Biochemistry & Cell Biology|January 22, 2016
Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumorsDilys T H Leung, Peter J Fuller, Simon ChuClinical Endocrinology|June 21, 2005
Seladin-1/DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumoursPeter J Fuller, Maria Alexiadis, Tom Jobling, et al.Journal of the Society for Gynecologic Investigation|June 28, 2005
Expression of steroid receptor coactivators in cultured cells from paired myometrial and fibroid tissuesSonay Hussein-Fikret, Peter J Fuller, Caroline E GargettThe Journal of Pathology|October 23, 2021
FOXL2C134W : much ado about something!†Peter J Fuller, Trang Nguyen, Maria Alexiadis, et al.Australian Journal of General Practice|June 15, 2019
Current pattern of primary aldosteronism diagnosis: Delayed and complicatedYin Yu Lim, Jimmy Shen, Peter J Fuller, et al.The Lancet. Diabetes & Endocrinology|November 14, 2025
Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysisSho Katsuragawa, Minh V Le, Peter J Fuller, et al.The Journal of Endocrinology|December 14, 2011
Mechanisms of ligand specificity of the mineralocorticoid receptorPeter J Fuller, Yizou Yao, Jun Yang, et al.Journal of Human Hypertension|April 29, 2020
Primary aldosteronism is a public health issue: challenges and opportunitiesRenata Libianto, Peter J Fuller, Morag J Young, et al.Journal of Human Hypertension|August 1, 2020
Identifying new cellular mechanisms of mineralocorticoid receptor activation in the heartMorag J Young, Monica Kanki, Peter J Fuller, et al.Pageof 20